143 results on '"Meiselbach, Mark K."'
Search Results
2. Deductible imputation in administrative medical claims datasets
3. Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States
4. Do minimum wage laws affect employer-sponsored insurance provision?
5. Impact of High Deductible Health Plans on U.S. Adults With Chronic Pain
6. Choice of high-deductible health plans among enrollees with a substance use disorder
7. Correction to: Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States
8. Participation, Pricing, and Enrollment in a Health Insurance “Public Option” : Evidence From Washington State’s Cascade Care Program
9. High deductible health plans and spending among families with a substance use disorder
10. Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
11. Commercial Insurer Market Power and Medicaid Managed Care Networks.
12. Unmet need for mental health care is common across insurance market segments in the United States
13. Racial and Ethnic Disparities in Geographic Availability of Buprenorphine.
14. Distributional Effects of Recent Health Insurance Expansions on Weight-Related Outcomes
15. Hospital Prices in Medicaid Managed Care
16. Do Insurers With Greater Market Power Negotiate Consistently Lower Prices for Hospital Care? Evidence From Hospital Price Transparency Data.
17. Do Insurers With Greater Market Power Negotiate Consistently Lower Prices for Hospital Care? Evidence From Hospital Price Transparency Data
18. Psychiatrist and Nonpsychiatrist Physician Network Breadth in Dual Eligible Special Needs Plans
19. Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
20. Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review
21. State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care
22. Trends in Medicare Advantage Participation Among Commercial Insurers.
23. Do High-Deductible Health Plans Incentivize Changing the Timing of Substance Use Disorder Treatment?
24. Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care
25. Why Are Some Value-Based Programs Successful?
26. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
27. sj-docx-1-mcr-10.1177_10775587231180667 – Supplemental material for Do High-Deductible Health Plans Incentivize Changing the Timing of Substance Use Disorder Treatment?
28. sj-docx-1-mcr-10.1177_10775587231167514 – Supplemental material for State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care
29. High-deductible Health Plans and Nonfatal Opioid Overdose.
30. The Impact of HDHPs on Service Use and Spending for Substance Use Disorders
31. Medicaid Managed Care: Access to Primary Care Providers Who Prescribe Buprenorphine
32. Participation, Pricing, and Enrollment in a Health Insurance “Public Option”: Evidence From Washington State's Cascade Care Program
33. Correction to: Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States
34. Effects of High-Deductible Health Plans on Enrollees With Mental Health Conditions With and Without Substance Use Disorders
35. Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
36. Physician Network Breadth and Plan Quality Ratings in Medicare Advantage
37. sj-pdf-1-mcr-10.1177_10775587211012992 – Supplemental material for Labor Market Concentration and Worker Contributions to Health Insurance Premiums
38. Frequency and Costs of Out-of-Network Bills for Outpatient Laboratory Services Among Privately Insured Patients
39. Labor Market Concentration and Worker Contributions to Health Insurance Premiums
40. Effects of High-Deductible Health Plans on Enrollees With Mental Health Conditions With and Without Substance Use Disorders.
41. Labor Market Concentration and Worker Contributions to Health Insurance Premiums.
42. Charges of COVID-19 Diagnostic Testing and Antibody Testing Across Facility Types and States
43. Large Self-insured Employers Lack Power to Effectively Negotiate Hospital Prices.
44. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
45. Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti
46. One‐Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study
47. Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer’s disease diagnosis: a pilot study in England
48. [P3-476]: IS THE ANNUAL WELLNESS VISIT ADEQUATE TO IMPACT COGNITIVE CARE?
49. Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England.
50. IS THE ANNUAL WELLNESS VISIT ADEQUATE TO IMPACT COGNITIVE CARE?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.